AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03655977
Drug: 68Ga-NODAGA-E[c(RGDyK)]2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before external beam radiation therapy (EBRT).
Trial: NCT03655977
Drug: 68Ga-NODAGA-E[c(RGDyK)]2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before brachytherapy (BT).
Trial: NCT03142620
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg twice daily
Trial: NCT03113396
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
Trial: NCT00935805
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable SC dose
Trial: NCT00934973
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: overencapsulated placebo tablets 1 tds for 6 weeks
Trial: NCT02709785
Drug: Placebo rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
Trial: NCT01976780
Drug: Artemether Lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02885441
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
Trial: NCT03742063
Drug: first-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
Trial: NCT02450058
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2, intravenously on day 1, every 21 days for six cycles
Trial: NCT02821858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered.
Trial: NCT04553406
Drug: SPR720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration
Trial: NCT04553406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration
Trial: NCT02623738
Drug: Placebo ophthalmic solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02870231
Drug: NNC9204-0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily subcutaneous (s.c., under the skin) administration.
Trial: NCT02870231
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily subcutaneous (s.c., under the skin) administration
Trial: NCT04553406
Drug: Open-label Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~* Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~* Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days.
Trial: NCT01240850
Drug: Methotrexate+Prednisone
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen
Trial: NCT03341260
Drug: Diclofenac Potassium 50mg Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
Trial: NCT03341260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo will be taken one hour before initiation of endodontic treatment.
Trial: NCT00317148
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT00789776
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00075959
Drug: NXY-059
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01676844
Drug: Oral thin film therapy (Potassium acid phosphate oral thin films)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.~Place a single OTF on the tongue, inside cheek or palate and allow to dissolve.
Trial: NCT01676844
Drug: Standard therapy (Potassium acid phosphate oral solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
Trial: NCT03949374
Drug: CRESTOR, reference formulation of rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of ROVASRO for hypercholesterolemia
Trial: NCT02484508
Drug: Kangguzengsheng capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
Trial: NCT03949374
Drug: ROVASRO, generic formulation of rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of CRESTOR for hypercholesterolemia
Trial: NCT01132417
Drug: In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
Trial: NCT01214239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a day
Trial: NCT01025791
Drug: MK-8266 0.1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
Trial: NCT01025791
Drug: MK-8266 1.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Trial: NCT00834613
Drug: Glucophage® XR 750 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 750 mg, single-dose fed
Trial: NCT04036409
Drug: Standard control of Systolic Blood Pressure (SBP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Trial: NCT01319968
Drug: Estriol 0.1% vaginal cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
Trial: NCT01025791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Trial: NCT02258880
Drug: SUN13837
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02258880
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02401737
Drug: NVR 3-778
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02401737
Drug: Placebo for NVR 3-778
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic the NVR 3-778 capsule
Trial: NCT03204123
Drug: Ga-HBED-iPSMA PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.
Trial: NCT03646162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02950233
Drug: NMDA placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID \[first week\]; 1 capsule BID \[following three weeks\]).
Trial: NCT02950233
Drug: Steroid placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
Trial: NCT04573309
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as tablets.
Trial: NCT03516487
Drug: SYNB1618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
Trial: NCT03516487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive placebo orally in a chilled buffered solution (100 mL).
Trial: NCT00660387
Drug: Levodopa carbidopa intestinal gel (LCIG)
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
Trial: NCT00660387
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00660387
Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00666354
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
Trial: NCT00666354
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
Trial: NCT01482221
Drug: AZD6765 iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
Trial: NCT01482221
Drug: AZD6765 iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
Trial: NCT01482221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 sodium chloride \[normal saline\] solution for injection by iv infusion
Trial: NCT00814957
Drug: GSK618334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 receptor antagonist
Trial: NCT00090545
Drug: BAY 43-9006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg BAY 43-9006 orally twice daily in 28 day cycles.
Trial: NCT04019574
Drug: CR845 0.5 mcg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mcg/kg IV CR845
Trial: NCT04019574
Drug: CR845 3 mcg/kg IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mcg/kg IV CR845
Trial: NCT03786692
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab
Trial: NCT03786692
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin + Pemetrexed + Bevacizumab
Trial: NCT04438044
Drug: ICP-022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICP-022 The drug product is a white, round, uncoated tablet
Trial: NCT04355598
Drug: placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
Trial: NCT04654429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Normal Saline 2cc will be given
Trial: NCT03143049
Drug: PCD
RxNorm normalized name: Eyefull PCD Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first).
Trial: NCT03143049
Drug: PD
RxNorm normalized name: PDO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first).
Trial: NCT01679041
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4
Trial: NCT01896479
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03321123
Drug: MB-CART19.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
Trial: NCT02117648
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02769624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 breaths of placebo (via inhalation devices) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
Trial: NCT01896479
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05311540
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00523991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation once daily of placebo matching tiotropium via handihaler
Trial: NCT01197287
Drug: QAK423A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04419584
Drug: Modified Qing-Ying Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal granules
Trial: NCT04419584
Drug: Identical looking placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granules
Trial: NCT02246660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be taken orally for 6 months.
Trial: NCT01963481
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00354601
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral capecitabine twice daily on days 1-21
Trial: NCT00131846
Drug: Thiazide diuretics
RxNorm normalized name: althiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any dosage, frequency, and duration
Trial: NCT00691704
Drug: Sequential Maintenance Therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who achieve \>partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved \> stable disease (SD) from maintenance (per discussion with physician):~* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~* Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~* Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle.
Trial: NCT00131846
Drug: No diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any antihypertensive regimen other than diuretics
Trial: NCT03450083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous placebo injection
Trial: NCT01819779
Drug: Exforge tab. 10/160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01819779
Drug: Lodivixx tab. 5/160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00151671
Drug: Oral Impact®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
Trial: NCT00151671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
Trial: NCT02669732
Drug: DS-8500a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT02669732
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT01832987
Drug: co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
Trial: NCT00859040
Drug: SOM230C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection in the buttocks every 28 days
Trial: NCT00697762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet twice daily for 12 weeks
Trial: NCT04523480
Drug: Testopel 75mg Drug Implant
RxNorm normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg Testosterone pellets administered subcutaneously.
Trial: NCT04523480
Drug: Testopel 100mg Drug Implant
RxNorm normalized name: testosterone Drug Implant [Testopel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Testosterone pellets administered subcutaneously.
Trial: NCT04523480
Drug: Testopel 200mg Drug Implant
RxNorm normalized name: testosterone Drug Implant [Testopel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Testosterone pellets administered subcutaneously.
Trial: NCT04059978
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo p.o, single oral dose (8 ml oily solution)
Trial: NCT04059978
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.1 µg/kg/min i.v. for 30 min
Trial: NCT01103648
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of simvastatin 20 mg administered once a day for 12 weeks
Trial: NCT04516096
Drug: AMX0035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day
Trial: NCT02689778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical tablets without active substance
Trial: NCT01103648
Drug: Combination Simvastatin plus Ezetimibe
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).~Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).~This Combination represents the experimental period of the present study.
Trial: NCT00005589
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03091634
Drug: xue-fu-zhu-yu capsule
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks
Trial: NCT03091634
Drug: xue-fu-zhu-yu capsule simulated agent
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks